Bradley Foster & Sargent Inc. CT reduced its position in AbbVie Inc (NYSE:ABBV) by 1.2% during the third quarter, HoldingsChannel reports. The firm owned 162,005 shares of the company’s stock after selling 1,889 shares during the quarter. Bradley Foster & Sargent Inc. CT owned 101.63% of AbbVie worth $14,396,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Acropolis Investment Management LLC bought a new position in AbbVie during the 2nd quarter valued at $106,000. Hudock Capital Group LLC raised its stake in shares of AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after purchasing an additional 806 shares during the period. Ffcm LLC raised its stake in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after purchasing an additional 963 shares during the period. Bristlecone Advisors LLC bought a new stake in shares of AbbVie during the 3rd quarter worth $113,000. Finally, BDO Wealth Advisors LLC bought a new stake in shares of AbbVie during the 2nd quarter worth $115,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

Shares of AbbVie Inc (ABBV) opened at $102.49 on Wednesday. AbbVie Inc has a twelve month low of $59.27 and a twelve month high of $103.00. The firm has a market capitalization of $163,380.00, a PE ratio of 24.88, a P/E/G ratio of 1.20 and a beta of 1.53. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. During the same quarter last year, the firm posted $1.21 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. analysts forecast that AbbVie Inc will post 5.54 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a $0.71 dividend. The ex-dividend date is Thursday, January 11th. This represents a $2.84 annualized dividend and a yield of 2.77%. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is 68.93%.

A number of equities research analysts have recently commented on the company. Vetr cut AbbVie from a “strong-buy” rating to a “buy” rating and set a $113.08 target price on the stock. in a research note on Monday, January 8th. Zacks Investment Research cut AbbVie from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Jefferies Group lifted their target price on AbbVie from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, January 4th. BMO Capital Markets set a $84.00 target price on AbbVie and gave the stock a “hold” rating in a research note on Thursday, January 11th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, January 2nd. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $100.94.

In other AbbVie news, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the completion of the transaction, the insider now owns 81,287 shares of the company’s stock, valued at approximately $7,360,537.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Richard A. Gonzalez sold 218,193 shares of AbbVie stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now directly owns 492,030 shares of the company’s stock, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. In the last three months, insiders sold 494,676 shares of company stock valued at $47,237,938. 0.23% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Bradley Foster & Sargent Inc. CT Sells 1,889 Shares of AbbVie Inc (ABBV)” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/bradley-foster-sargent-inc-ct-sells-1889-shares-of-abbvie-inc-abbv/1810144.html.

AbbVie Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with Analyst Ratings Network's FREE daily email newsletter.